NDAORALTABLET
Approved
Dec 1996
Lifecycle
LOE Approaching
Competitive Pressure
30/100
Clinical Trials
2
Data completeness
5/8 — Partial
ZYFLO (zileuton) by Chiesi is 5-lipoxygenase inhibitors [moa]. Approved for 5-lipoxygenase inhibitor [epc]. First approved in 1996.
Drug data last refreshed 18h ago · AI intelligence enriched 2w ago
AI summarySynthesized from FDA + DailyMed + ClinicalTrials.gov data
ZYFLO (zileuton) is an oral small-molecule 5-lipoxygenase inhibitor approved in 1996 for asthma and used off-label across pulmonary fibrosis, Hermansky-Pudlak Syndrome, lung cancer, and chronic myelogenous leukemia. It reduces leukotriene production, suppressing inflammation and bronchoconstriction in airways and potentially tumor microenvironments.
$3MPart D
LOE ApproachingMinimal commercial momentum with only $3M Part D spend and <1K annual claims signals a mature, niche product with small commercial team and limited growth opportunity.
Mechanism of Action
5-Lipoxygenase Inhibitors
Pharmacologic Class:
5-Lipoxygenase Inhibitor
Indications
Indication data is being enriched from DailyMed and FDA labeling. Check back soon for approved therapeutic uses.
Clinical Trials (2)
Evaluating the Safety of Zileuton (Zyflo®) in Combination With Dasatinib (Sprycel®) in Chronic Myelogenous Leukemia
Started Jan 2014
2 enrolled
Chronic Myelogenous Leukemia
Carboplatin and Gemcitabine Combined With Celecoxib and/or Zileuton in Treating Patients With Advanced Non-Small Cell Lung Cancer
Started Dec 2003
140 enrolled
Lung Cancer
Career Relevance
ZYFLO shows zero linked job openings in current market data, reflecting its status as a mature, niche asset with minimal commercial investment. Career opportunities are severely limited and primarily defensive (maintaining current market share) rather than expansionary.
Worked on ZYFLO at Chiesi? Share your interview experience or compensation data (+7 days Pro)
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.